Phase 1 N=27 Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy
Birch Pollen Allergy
Primary: Treatment Emergent Adverse Events — 13; 3; 81; 2 number of adverse events per arm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=242 Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)
HIV-1 Infection
Primary: Number of Participants With ≥1 Adverse Event (AE) Through Week 36 — 66; 63; 36 Participants
Early Phase 1 N=43 Brain Imaging of Cannabinoid Receptors
Cannabis Use Disorder · Cannabis Dependence, Continuous
Primary: Distribution Volume (VT) — 1.27; 1.54; 1.14; 1.31 mL/cm^3 — p=0.02
N/A N=60 Evaluation of 19-gauge vs 21-gauge EBUS TBNA in Assessing Thoracic Lymphadenopathy
Enlarged Lymph Nodes (Excluding Infective)
Primary: Diagnostic Yield — 69; 68; 57; 57 lymph nodes
N/A N=19 Affordable Mobile Robots for the Elderly
Aging
Primary: Usability Scale for Deployment 1 — 78.13; 77.08 score on a scale
Phase 3 N=230 A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily
Presbyopia
Primary: Percentage of Participants Gaining 3 Lines or More in Mesopic, High-Contrast, Binocular Distance-Corrected Near Visual Acuity (DCNVA) With No More Than 5-Letter Loss in…
N/A N=72 Mobile Technology and Data Analytics to Identify Real-time Predictors of Caregiver Well-Being
Caregivers
Primary: Feasibility and Acceptability as Measured by the Percentage of Agree or Strongly Agree Responses to the Individual Items on the Feasibility Questionnaire — 62; 63; 64…
N/A N=15 Low Frequency TMS for Depression in Epilepsy
Epilepsy · Depressions, Refractory
Primary: Change in Seizure Frequency Expressed as the Average Number of Seizures Experienced by All Participants and Recorded at Specified Time Points Throughout the Study…
N/A N=50 My Baby My Move A Community Wellness Intervention
Gestational Weight Gain
Primary: Weight — 162.9; 162.3 pounds
Phase 4 N=64 Study on the Effects of Intravenous Dexmedetomidine on Pain in Patients Undergoing Elective Spinal Surgery
Chronic Pain
Primary: Morphine Equivalents Used During the First 48 Hours Post-Surgery — 180; 142.5 morphine milligram equivalent (MME)
Phase 3 N=730 A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety
Resistant Hypertension
Primary: Change From Baseline to Week 4 of Double-blind Treatment in Mean Trough Sitting Systolic Blood Pressure (SiSBP) Measured by Automated Office Blood Pressure Measurement…
Phase 2 N=20 Vitamin C Infusion for TReatment in Sepsis and Alcoholic Hepatitis
Alcoholic Hepatitis · Sepsis
Primary: Change in Model for End Stage Liver Disease (MELD) Score — -0.13; -2.9; -2.3; -2.4 score on a scale
Phase 2 N=62 Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment
Advanced Renal Cell Carcinoma · Metastatic Renal Cell Carcinoma
Primary: Progression Free Survival (PFS) — 7.5; 4.6; 6.8 Months
Phase 1 N=46 PET Imaging of the Dopaminergic and Serotonergic Systems in Treated HIV Positive Subjects
Depression · HIV Infections · HIV-Associated Cognitive Motor Complex
Primary: Influx Constant (Ki) for 18F-FDOPA PET. — 0.01415; 0.01409; 0.01588; 0.01592 min-1
Phase 2 N=33 Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
Lymphoma
Primary: Number of Participants With at Least One Dose Limiting Toxicity (DLT) — 3; 1; 0; 0 Participants